IFNA1 and neoplasm: Early work from Dr. Maio’s group demonstrated an upregulation of the expression of HLA class I antigens, tumor antigens, components of the interferon (IFN) pathway and co-stimulatory molecules in tumor cells upon treatment with the demethylating agent 5-aza 2‘-deoxycytidine (DAC) thereby inducing CTL recognition.